Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

15.89 -0.11 (-0.69%)
Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On ↗
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors. 
Via InvestorPlace
News headline image
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 ↗
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape ↗
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia. 
Via Benzinga
News headline image
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning! 
Via InvestorPlace
News headline image
Maker Of Wilson Tennis Rackets Raises $1.37 Billion In Discounted IPO ↗
Amer Sports, the maker of Wilson tennis rackets and a host of other sports equipment, raised about $1.37 billion in its initial public offering, which was priced below the previously expected $16-$18... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.